MediWound Ltd. (MDWD) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, MediWound Ltd.'s filing signal continuing negative.

MediWound Ltd. is an Israeli biopharmaceutical company specializing in non-surgical tissue repair solutions, leveraging a patented enzymatic technology platform. Its flagship product, NexoBrid, is a topical biological orphan drug approved in over 45 countries for eschar removal in burn patients, with significant commercialization efforts in North America through its partner Vericel. The company is also advancing EscharEx, a bromelain-based therapy for chronic wound debridement, which is currently in Phase III clinical trials and has shown promising results in Phase II studies. MediWound operates a cGMP-certified manufacturing facility in Yavne, Israel, and is expanding its production capacity to meet global demand. The company's strategy focuses on addressing unmet medical needs in wound and burn care, aiming to improve patient outcomes and reduce healthcare costs.

Revenues are primarily driven by sales of NexoBrid to burn centers and hospitals globally, as well as through distribution agreements. The company also generates revenue from development services provided to government entities like BARDA and the U.S. Department of War/MTEC.